wäre man ja dumm, wenn man morgens kafut, denn dieses Kack Spiel ist ja immer das gleiche. Die treiben den Kurs hier auch runter, so wie sie ihn haben wollen
... Confirmed the T2SARS-CoV-2TM Panel is capable of detecting the India B.1.617 variant of the SARS-CoV-2 virus based on sequence alignments and in silico analysis
T2 Biosystems T2SARS-CoV-2 Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus
…is capable of detecting the Mu (B.1.621) and Iota (B.1.526) variants of the SARS-CoV-2 virus, which were recently confirmed to be present in the United States.
“We are proud to announce our technology is capable of detecting additional COVID-19 variants including Mu and Iota, enabling healthcare providers with the confidence to make more informed decisions about their patients’ health,” said T2 Biosystems’ Chairman and CEO, John Sperzel.
Like the variants identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1), the Mu and Iota variants contain multiple mutations, most reflected in the S gene, which encodes the spike protein. Specific analyses of sequences for the Mu and Iota variants confirmed that the T2SARS-CoV-2 Panel should be able to detect this variant with high confidence and reliability. This analysis expands the proven utility of the panel beyond the previously announced capability to detect the Delta (B.1.617.2) variant along with the B.1.1.7, B.1.351, and P.1 variants.
ich bin mal wieder eingestiegen bei t2 diese Woche. verfolge die schon recht lange und hatte hin und wieder ein gutes Händchen bei denen. vielleicht klappt's ja diesmal wieder und es geht bald bergauf...
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results
Recent Highlights (unaudited)
•Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million, representing an increase of 53% and 43%, respectively compared to the prior year
•Achieved fourth quarter total revenue of $6.6 million, including fourth quarter product revenue of $4.0 million
•Executed contracts for 32 T2Dx Instruments in 2021, including 17 T2Dx Instrument contracts during the fourth quarter, consisting of 3 from the U.S. and 14 from outside the U.S.
•Generated full year 2021 U.S. sepsis test panel revenue of $5.1 million, representing growth of 46% compared to the prior year
•Hired a veteran Chief Commercial Officer and significantly expanded our sales, marketing, clinical and medical affairs teams
•Initiated clinical trials for the T2Resistance Panel and T2Biothreat Panel in December, enabling potential filing of FDA submissions for both products during 2022
•Expanded commercialization in Asia Pacific and Latin America regions by entering into distributor agreements in Taiwan, Singapore, South Korea, and Mexico
•Cash, cash equivalents, marketable securities, and restricted cash totaled $33.7 million as of December 31, 2021
Thread abonnieren
